REPL US Equity
Replimune Group, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1737953 · FY ends Mar 31$14.81
-0.77 (-4.94%)
USD · as of 2026-08-19 · marketstack
Short interest· FINRA consolidated · settlement 2026-07-31
6 settlement cycles| Shares short | 27.5M |
| % of shares out | 29.2% |
| Days to cover | 3.3 |
| Δ vs 2026-07-15 | +16.4% |
bars = shares short · line = days to cover (own scale)
| Settlement | Shares short | Δ vs prior | Avg daily volume | Days to cover |
|---|
| 2026-07-31 | 27,540,626 | +16.4% | 8,449,526 | 3.3 |
| 2026-07-15 | 23,654,362 | -0.1% | 2,504,998 | 9.4 |
| 2026-06-30 | 23,666,879 | +3.4% | 3,717,912 | 6.4 |
| 2026-06-15 | 22,885,091 | -11.8% | 4,731,854 | 4.8 |
| 2026-05-29 | 25,954,343 | +9.7% | 8,826,729 | 2.9 |
| 2026-05-15 | 23,657,005 | +11.8% | 8,360,368 | 2.8 |
FINRA Rule 4560 · twice monthly, published ~a week later.
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
